focus -WSS

focus

author：focus 2025-10-01 11:46:32 - browse：4485

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Pregnancy ages women, but effects reverse after delivery

WSS

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Pregnancy ages women, but effects reverse after delivery

Cancer, immunology, HIV research ensnared in fetal tissue politics

Asbestos ban is immediate, but health effects will linger for decades

Pfizer, Moderna say biotech, pharma drug development is a sprint

Texas board proposes rules on abortion law emergency exemption

explore

focus

explore

Supreme Court strikes down use of affirmative action

WATCH: Why do fingernails fall off when they're damaged?

Virginia high school admissions case could be legal follow

Do masks work? RCTs can't tell us

Alkermes shareholders re

6 surprising facts about sugar

As demand for Covid shots wanes, Moderna seeks its next success

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Cancer drug shortages should be causing more outrage

The story of mRNA: From a loose idea to a tool that may help curb Covid

leisure time

What would happen to your eyes if you looked at the solar eclipse?

Colonoscopy at 40? Study finds a possible benefit

Death of patient in Alzheimer’s trial raises question of possible risks

Why drug prescriptions should include diagnoses

In areas with more Black doctors, Black people live longer

U.K. officials, researchers try to ease path for bespoke genetic treatments

hotspot

Wikipedia

knowledge

knowledge